COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current e...

Descripción completa

Detalles Bibliográficos
Autores principales: Agrati, Chiara, Di Cosimo, Serena, Fenoglio, Daniela, Apolone, Giovanni, Ciceri, Fabio, Ciliberto, Gennaro, Baldanti, Fausto, Costantini, Massimo, Giannarelli, Diana, Ippolito, Giuseppe, Locatelli, Franco, Mantovani, Alberto, Morrone, Aldo, Tagliavini, Fabrizio, Uccelli, Antonio, Zinzani, Pier Luigi, Silvestris, Nicola, Rescigno, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383886/
https://www.ncbi.nlm.nih.gov/pubmed/34447374
http://dx.doi.org/10.3389/fimmu.2021.704110
Descripción
Sumario:Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

Ejemplares similares